pre-IPO PHARMA

COMPANY OVERVIEW

I-Mab is a dynamic and fast-growing global player exclusively focused on developing first-in-class and best-in-class biologics in the areas of immuno-oncology and autoimmune diseases through internal R&D capabilities and global partnerships. I-Mab’s pipeline is driven by the company’s development strategy to address unmet needs in China and to bring innovative assets to the world. The company is prepared to submit additional INDs in order to initiate clinical trials in China and the U.S., including multiple Phase 2 and Phase 3 studies. I-Mab is on a fast track toward becoming an end-to-end fully integrated biopharma company. The company has been well-recognized by capital markets by successfully raising approximately USD 370 million within 12 months, with the recent USD 220 million Series C financing representing one of the largest amounts ever raised by an innovative biotech company in China.


LOCATION

  • Shanghai, , China
  • Beijing, , China
  • Rockville, MD, USA

  • THERAPEUTIC AREAS

  • Autoimmune Disease
  • Oncology
  • Pediatric

  • WEBSITE

    https://www.i-mabbiopharma.com/en/


    CAREER WEBSITE

    None


    SOCIAL MEDIA


    INVESTORS

    ally-bridge-group c-bridge-capital cdh-investment edbi hillhouse-capital hony-capital hopu-investments tasly-capital

    PRESS RELEASES


    Dec 13, 2021

    I-MAB Biopharma and AGC Biologics Partner on Late-Phase Project


    Jan 3, 2020

    I-Mab Biopharma Announces Dosing of First Patient in a Pivotal Study of TJ202/MOR202 in Multiple Myeloma in Mainland China


    Nov 14, 2019

    I-Mab Biopharma Receives IND Approval from NMPA to Initiate Clinical Trials for its Anti-GM-CSF Monoclonal Antibody TJM2 in China


    Oct 14, 2019

    I-Mab Biopharma and MorphoSys Announce IND Clearance to Initiate Clinical Trials of TJ202/MOR202 for the Treatment of Multiple Myeloma in Mainland China


    Oct 4, 2019

    I-Mab Biopharma Receives IND Approval in China for Proprietary CD73 Antibody TJD5


    For More Press Releases


    Google Analytics Alternative